




Therapy

Melatonin analogous for cancer treatment

A research group from the Andalusian Public Health Service (SSPA) has developed a melatonin analogous (Agomelatine) to treat cancer.

**TECHNOLOGY
TRANSFER OFFICE**
Andalusian Public Health System



Description

Melatonin affects cell proliferation in a variety of tumor cell lines, both in physiological and pharmacological concentrations.

This research group has demonstrated that a melatonin analogue, called agomelatine, inhibits the growth of cell lines of colon cancer *in vitro* and *in vivo*, suggesting the oncostatic / cytotoxic role of this compound.

sexual side effects. Thus, extended preclinical studies could not be necessary to start clinical trials with agomelatina.



Intellectual Property

This technology is protected by a Spanish patent application with the possibility of international extension.



Advantages

This pharmaceutical composition may be administered by any suitable method, such as intravenous infusion and oral, topical or parenteral routes. The combined use with other components is proposed, as well as the preparation of a food composition as a nutritional or dietary supplement.

Agomelatine is a safe compound to be administered to humans, as it is already commercialized under trade names like Valdoxan, Melitor, Thymanax as a melatonergic antidepressant. It is marketed for the treatment of major depressive disorder and has been reported not to produce discontinuation syndrome or



Aims

This research group is looking to establish a license agreement or agreement for public-private partnership for the development of technology.



Classification

Area: Therapy
Pathology: Oncology